ASP Isotopes’ (ASPI) “Buy” Rating Reaffirmed at Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of ASP Isotopes (NASDAQ:ASPI) in a report released on Monday,Benzinga reports. They currently have a $11.00 price target on the stock.

Several other equities analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, November 19th. Loop Capital set a $15.00 price objective on shares of ASP Isotopes in a research report on Monday, October 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.00.

ASP Isotopes Trading Up 3.2%

Shares of NASDAQ ASPI opened at $6.16 on Monday. The company has a market cap of $682.77 million, a price-to-earnings ratio of -4.85 and a beta of 3.28. ASP Isotopes has a fifty-two week low of $3.65 and a fifty-two week high of $14.49. The business’s 50 day moving average price is $9.45 and its 200-day moving average price is $8.83. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings data on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.05). ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $2.25 million. On average, sell-side analysts expect that ASP Isotopes will post -0.24 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Todd Wider sold 74,108 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $8.76, for a total transaction of $649,186.08. Following the completion of the transaction, the director owned 710,230 shares of the company’s stock, valued at $6,221,614.80. This trade represents a 9.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paul Elliot Mann sold 81,077 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $8.39, for a total value of $680,236.03. Following the sale, the chief executive officer directly owned 8,084,191 shares in the company, valued at $67,826,362.49. This represents a 0.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 473,699 shares of company stock worth $4,225,902. Company insiders own 21.40% of the company’s stock.

Institutional Investors Weigh In On ASP Isotopes

Several hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new position in shares of ASP Isotopes in the 3rd quarter valued at $34,000. Ameritas Investment Partners Inc. increased its holdings in ASP Isotopes by 41.2% in the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock valued at $40,000 after buying an additional 1,600 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares in the last quarter. Close Asset Management Ltd acquired a new position in shares of ASP Isotopes in the third quarter worth about $72,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of ASP Isotopes by 96.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after acquiring an additional 5,353 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.